Literature DB >> 2384112

Pharmacokinetics of vinpocetine and its main metabolite apovincaminic acid before and after the chronic oral administration of vinpocetine to humans.

P Miskolczi1, K Kozma, M Polgár, L Vereczkey.   

Abstract

The pharmacokinetics of vinpocetine (Cavinton) and of its main metabolite apovincaminic acid (AVA), has been studied in 5 healthy male volunteers after the administration of 3 x 5 and 3 x 10 daily doses of vinpocetine for seven days. The pharmacokinetic curves of both vinpocetine and AVA have been determined prior to the chronic administration and on the last day of the treatment, whereas between the 2nd and 6th days, concentration was measured once daily. On the basis of these pharmacokinetic studies it can be concluded that both vinpocetine and AVA show linear pharmacokinetics at the doses used and that there is no accumulation or autoinduction.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2384112     DOI: 10.1007/BF03190120

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  10 in total

1.  Ethyl apovincaminate therapy in neurovascular diseases.

Authors:  A Szobor; M Klein
Journal:  Arzneimittelforschung       Date:  1976

2.  General and cerebral haemodynamic activity of ethyl apovincaminate.

Authors:  E Kárpáti; L Szporny
Journal:  Arzneimittelforschung       Date:  1976

3.  Protective activity of ethyl apovincaminate on ischaemic anoxia of the brain.

Authors:  K Biró; E Kárpáti; L Szporny
Journal:  Arzneimittelforschung       Date:  1976

4.  Rheoencephalographic and psychological studies with ethyl apovincaminate in cerebral vascular insufficiency.

Authors:  D Hadjiev; S Yancheva
Journal:  Arzneimittelforschung       Date:  1976

5.  Effect of ethyl apovincaminate on cerebral circulation of dogs under normal conditions and in arterial hypoxia.

Authors:  P Bencsáth; L Debreczeni; L Takács
Journal:  Arzneimittelforschung       Date:  1976

6.  Determination of apovincaminic acid in biological samples by high-performance liquid chromatography.

Authors:  M Kozma; P Pudleiner; L Vereczkey
Journal:  J Chromatogr       Date:  1982-05-28

7.  Pharmacokinetics of vinpocetine and its metabolite, apovincaminic acid, in plasma and cerebrospinal fluid after intravenous infusion.

Authors:  M Polgár; L Vereczkey; I Nyáry
Journal:  J Pharm Biomed Anal       Date:  1985       Impact factor: 3.935

8.  Pharmacokinetics of vinpocetine in humans.

Authors:  L Vereczkey; G Czira; J Tamás; Z Szentirmay; Z Botár; L Szporny
Journal:  Arzneimittelforschung       Date:  1979

9.  Pharmacokinetics of vinpocetine and apovincaminic acid in patients with impaired renal function.

Authors:  P Miskolczi; L Vereczkey; L Szalay; C S Göndöcs
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1984 Apr-Jun       Impact factor: 2.441

10.  Effect of age on the pharmacokinetics of vinpocetine (Cavinton) and apovincaminic acid.

Authors:  P Miskolczi; L Vereczkey; L Szalay; C Göndöc
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

  10 in total
  3 in total

1.  Systemic exposure of vinpocetine in pregnant Sprague Dawley rats following repeated oral exposure: An investigation of fetal transfer.

Authors:  Suramya Waidyanatha; Heather Toy; Natalie South; Seth Gibbs; Esra Mutlu; Brian Burback; Barry S McIntyre; Natasha Catlin
Journal:  Toxicol Appl Pharmacol       Date:  2017-11-15       Impact factor: 4.219

2.  Phosphodiesterase inhibition increases CREB phosphorylation and restores orientation selectivity in a model of fetal alcohol spectrum disorders.

Authors:  Thomas E Krahe; Weili Wang; Alexandre E Medina
Journal:  PLoS One       Date:  2009-08-14       Impact factor: 3.240

3.  Updates of Recent Vinpocetine Research in Treating Cardiovascular Diseases.

Authors:  Chongyang Zhang; Chen Yan
Journal:  J Cell Immunol       Date:  2020
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.